Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Lytenava 25 mg/mL solution for injection {equilateral_black_triangle}

Active Ingredient:
Bevacizumab gamma
Company:  
Outlook Therapeutics Ltd See contact details
ATC code: 
S01LA08
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Guide to Lytenava (bevacizumab gamma) 25 mg/mL solution for injection

This guide is provided by Outlook Therapeutics for adult patients who have been prescribed LYTENAVA™ treatment for neovascular (wet) AMD.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Outlook Therapeutics Ltd
Company image
Address
3rd Floor, One London Square, Cross Lanes, Guildford, Surrey, GU1 1UN, UK
Telephone
+44 (0)20 3872 3526
Medical Information Direct Line
+44 (0)20 3872 3526
Medical Information e-mail
[email protected]
WWW
https://outlooktherapeutics.uk/